GLPwatch
Papers (12034)
Page 190 of 201, ranked by citation count.
- [SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].
- Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials.
- Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity.
- In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than oral semaglutide at 52 wk.
- Variant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.
- [IDegLira receives extended approval].
- Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights.
- Weight Loss Medications in Youth: Decision-Making Experiences, Eating Behaviors, and Uncertainty About Endpoint.
- Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.
- Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records.
- Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.
- Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy.
- PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction.
- Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.
- Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report.
- Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.
- SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey.
- Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
- Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.
- Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome.
- Sustained metabolic control in latent autoimmune diabetes in adults (LADA) with semaglutide therapy in a patient with multiple autoimmune comorbidities: a case report and literature review.
- [In patients with obesity and moderate to severe obstructive sleep apnea, is tirzepatide effective in reducing the apnea-hypopnea index compared to placebo, and is it safe?]
- Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
- THE EFFECT OF EXENATIDE THERAPY IN PREVIOUSLY INSULIN-TREATED TYPE 2 DIABETIC PATIENTS.
- GLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications.
- New drugs 2015, part 3.
- ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
- Insulin Autoimmune Syndrome: Imaging Findings and Uptake Pattern With 68 Ga-Exendin-4 and 68 Ga-DOTATATE PET-CT.
- Finerenone and semaglutide: Role in heart failure with reduced ejection fraction.
- The Impact of Semaglutide on Metabolic Syndrome: A Case Report.
- Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.
- Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.
- Inflammatory optic neuritis and scleritis following commencement of semaglutide: a case report.
- Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide.
- Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report.
- Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
- Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL).
- Sémaglutide et tirzépatide : nouvel espoir dans le traitement de l’insuffisance cardiaque ?
- Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
- Tirzepatide attenuates neurotoxicity by suppressing inflammation, apoptosis and restoring neurotrophin expression in an Alzheimer's disease-like rat model.
- Females are protected from semaglutide-induced muscle loss in <i>ob/ob</i> mice.
- Angioedema After Accidental Semaglutide Dosing Error: A Case Report.
- Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism.
- Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report.
- Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials.
- Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide.
- Signal thresholds and causal inference in pharmacovigilance studies of glucagon-like Peptide-1 receptor agonists.
- Comment on "Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes".
- The Peptide Paradox in Pharmacology of Obesity.
- Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
- [Victoza changes diabetes and lives of patients 5 years already].
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
- Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.
- Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.
- Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists.
- Oppositely biased glucagon-like peptide-1 receptor agonism does not differentially affect lipid metabolism in APOE*3-Leiden CETP mice.
- Tirzepatide - A major breakthrough in the fight against obesity.
- Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.
- Empagliflozin and dulaglutide: community awareness project promotes improved access to newly funded medications for Pacific patients with type 2 diabetes.